Canakinumab for the treatment of systemic juvenile idiopathic arthritis

References

• Prakken B, Albani S, Martini A. Juvenile idiopathic arthritis. Lancet 2011;377:2138-49
   PubMed Web of Science ®Google Scholar
• Petty RE, Southwood TR, Baum J, et al. Revision of the proposed classification criteria for juvenile idiopathic arthritis: durban, 1997. J Rheumatol 1998;25:1991-5
   PubMedGoogle Scholar
• Still GF. On a form of chronic joint disease in children. Med Chir Trans 1897;80:47-59
   PubMedGoogle Scholar
• Schneider R, Laxer RM. Systemic onset juvenile rheumatoid arthritis. Baillieres Clin Rheumatol 1998;12:245-71
   PubMed Web of Science ®Google Scholar
• Lomater C, Gerloni V, Gattinara M, et al. Systemic onset juvenile idiopathic arthritis: a retrospective study of 80 consecutive patients followed for 10 years. J Rheumatol 2000;27:491-6
   PubMed Web of Science ®Google Scholar
• Singh-Grewal D, Schneider R, Bayer N, Feldman BM. Predictors of disease course and remission in systemic juvenile idiopathic arthritis: significance of early clinical and laboratory features. Arthritis Rheum 2006;54:1595-601
   PubMedGoogle Scholar
• Lang BA, et al. Radiologic features of systemic onset juvenile rheumatoid arthritis. J Rheumatol 1995;22:168-73
   PubMedGoogle Scholar
• Hadchouel M, Prieur AM, Griscelli C. Acute hemorrhagic, hepatic, and neurologic manifestations in juvenile rheumatoid arthritis: possible relationship to drugs or infection. J Pediatr 1985;106:561-6
   PubMed Web of Science ®Google Scholar
• Ramanan AV, Schneider R. Macrophage activation syndrome--what’s in a name!. J Rheumatol 2003;30:2513-16
   PubMedGoogle Scholar
• Grom AA. NK dysfunction: a common pathway in systemic onset juvenile rheumatoid arthritis, macrophage activation syndrome and hemophagocytic lymphohistiocytosis. Arthritis Rheum 2004;50:689-98
   PubMed Web of Science ®Google Scholar
• Filipovich HA. Hemophagocytic lymphohistiocytosis. Immunol Allergy Clin N Am 2002;22:281-300
   Web of Science ®Google Scholar
• Mellins ED, Macubas C, Grom AA. Pathogenesis of systemic juvenile idiopathic arthritis: some answers, more questions. Nat Rev Rheumatol 2011;7:416-26
   PubMed Web of Science ®Google Scholar
• Hull KM, Shoham N, Chae JJ, et al. The expanding spectrum of systemic autoinflammtory disorders and their rheumatic manifestations. Curr Opin Rheumatol 2003;15:61-9
   PubMed Web of Science ®Google Scholar
• Pascual V, Allantaz F, Arce E, et al. Role of interleukin-1 (IL-1) in the pathogenesis of systemic onset juvenile idiopathic arthritis and clinical response to IL-1 blockade. J Exp Med 2005;201:1479-86
   PubMed Web of Science ®Google Scholar
• De Benedetti F, Martini A. Is systemic juvenile rheumatoid arthritis an interleukin 6 mediated disease? J Rheumatol 1998;25:203-7
   PubMed Web of Science ®Google Scholar
• Giannini EH, Ruperto N, Ravelli A, et al. Preliminary definition of improvement in juvenile arthritis. Arthritis Rheum 1997;40:1202-9
   PubMed Web of Science ®Google Scholar
• Singh G, Athreya BH, Fries JF, Goldsmith DP. Measurement of health status in children with juvenile rheumatoid arthritis. Arthritis Rheum 1994;37:1761-9
   PubMed Web of Science ®Google Scholar
• Brunner HI, Lovell DJ, Finck BK, Giannini EH. Preliminary definition of disease flare in juvenile rheumatoid arthritis. J Rheumatol 2002;29:1058-64
   PubMed Web of Science ®Google Scholar
• Woo P. Systemic juvenile idiopathic arthritis: diagnosis, management, and outcome. Nat Clin Pract Rheumatol 2006;2(1):28-34
   PubMedGoogle Scholar
• Verbsky JW, White AJ. Effective use of the recombinant interleukin 1 receptor antagonist anakinra in therapy resistant systemic onset juvenile rheumatoid arthritis. J Rheumatol 2004;31:2071-5
   PubMed Web of Science ®Google Scholar
• Irigoyen PI, Olson J, Hom C, Ilowite NT. Treatment of systemic onset juvenile rheumatoid arthritis with anakinra. Arthritis Rheum 2004;50(suppl):S437
   Google Scholar
• Nigrovic PA, Mannion M, Prince FH, et al. Anakinra as first-line disease-modifying therapy in systemic juvenile idiopathic arthritis: report of forty-six patients from an international multicenter series. Arthritis Rheum 2011;63:545-55
   PubMed Web of Science ®Google Scholar
• Sandborg C, Mellins ED. A new era in the tretament of systemic juvenile idiopathic arthritis. N Engl J Med 2012;367:2439-40
   PubMed Web of Science ®Google Scholar
• Yokota S, Imagawa T, Mori M, et al. Efficacy and safety of tocilizumab in patients with systemic-onset juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled, withdrawal phase III trial. Lancet 2008;371:998-1006
   PubMed Web of Science ®Google Scholar
• De Benedetti F, Brunner HI, et al. Tocilizumab in systemic juvenile idiopathic arthritis: a randomized trial. N Engl J Med 2012;367:2385-95
   PubMed Web of Science ®Google Scholar
• Kineret (Anakinra), Highlights of prescribing information. Swedish Orphan Biovitrum AB; Stockholm, Sweden: 2013
   Google Scholar
• Quartier P, Allantaz F, Cimaz R, et al. A multicentre, randomised, double-blind, placebo-controlled trial with the interleukin-1 receptor antagonist anakinra in patients with systemic-onset juvenile idiopathic arthritis (ANAJIS trial). Ann Rheum Dis 2011;70:747-54
   PubMed Web of Science ®Google Scholar
• Arcalyst [rilonacept], prescribing information. Tarrytown Regeneron Pharamaceuticals; 2010
   Google Scholar
• Lovell DJ, Giannini EH, Reiff AO, et al. Long-term safety and efficacy of Rilonacept in patients with systemic juvenile idiopathic arthritis. Arthritis Rheum 2013;65:2486-96
   PubMed Web of Science ®Google Scholar
• Ilowite NT, Prather K, Lokhnygina Y, et al. The randomized placebo phase study of Rilonacept in the treatment of systemic juvenile idiopathic arthritis. Arthritis Rheum 2014;66(9):2570-9
   PubMed Web of Science ®Google Scholar
• ILARIS, prescribing information. Novartis Pharmaceuticals Corp; East Hanover, NJ, USA: 2013
   Google Scholar
• Ruperto N, et al. A phase II, multicenter, open-label study evaluating dosing and preliminary safety and efficacy of canakinumab in systemic juvenile idiopathic arthritis with active systemic features. Arthritis Rheum 2012;64:557-67
   PubMed Web of Science ®Google Scholar
• Lachmann HJ, Kone-Paut I, Kuemmerle-Deschner JB, et al. Use of canakinumab in the cryopyrin-associated periodic syndrome. N Engl J Med 2009;360:2416-25
   PubMed Web of Science ®Google Scholar
• Kuemmerle-Deschner JB, Ramos E, Blank N, et al. Canakinumab (ACZ885, a fully human IgG1 anti-IL-1beta mAb) induces sustained remission in pediatric patients with cryopyrin-associated periodic syndrome (CAPS). Arthritis Res Ther 2011;13:R34
   PubMed Web of Science ®Google Scholar
• Ruperto N, Brunner HI, Quartier P, et al. Two randomized trials of canakinumab in systemic juvenile idiopathic arthritis. N Engl J Med 2012;367:2396-406
   PubMed Web of Science ®Google Scholar
• Grom AA, Brunner HI, Ruperto N, et al. Canakinumab is systemic juvenile idiopathic arthritis: impact on the rate and clinical presentation of macrophage activation syndrome. abstr EULAR 2014
   Google Scholar
• Brunner HI, Quartier P, Constantin T, et al. Canakinumab in the treatment of systemic juvenile idiopathic arthritis: results from a 12-week pooled post-hoc analysis for efficacy. Arthritis Rheum 2013;65(S10):S112-13
   Google Scholar
• Quartier P, Grom AA, Ruperto N, et al. Efficacy of canakinumab in biologic naïve versus previously biologic-exposed SJIA patients. Ann Rheum Dis 2014; 73(Suppl 2): Abstract FRI 0528
   Google Scholar
• DeWitt EM, et al. Consensus treatment plans for new-onset systemic juvenile idiopathic arthritis. Arthritis Care Res 2012;64:1001-10
   PubMed Web of Science ®Google Scholar
• Kimura Y, Morgan Dewitt E, Beukelman T, members of the Juvenile Idiopathic Arthritis Disease Specific Research Committee of the Childhood Arthritis and Rheumatology Research Alliance. Adding canakinumab to the childhood arthritis and rheumatology research alliance consensus treatment plans for systemic juvenile idiopathic arthritis. Arthritis Care Res (Hoboken) 2014;16(9):1430-1
   Google Scholar
• Ringold S, Weiss PF, Beukelman T, et al. 2013 update of the 2011 American College of Rheumatology recommendations for the treatment of juvenile idiopathic arthritis: recommendations for the medical therapy of children with systemic juvenile idiopathic arthritis and tuberculosis screening among children receiving biologic medications. Arthritis Care Res 2013;65:1551-63
   PubMed Web of Science ®Google Scholar
• Brachat A, Grom AA, Wulffraat N, et al. Changes in. gene expression and inflammatory proteins in systemic juvenile idiopathic arthritis patients on canakinumab therapy. Ann Rheum Dis 2014; 73(Suppl 2): Abstract OP0007
   Google Scholar